EA
SLNO

Emerald Advisers’s Soleno Therapeutics SLNO Stock Holding History

Emerald Advisers’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-274,138
Closed -$9.18M – 263
2026
Q1 		$9.18M Sell
274,138
-138,513
-34% -$5.43M 0.29% 103
2025
Q4 		$19.1M Sell
412,651
-215,105
-34% -$11.8M 0.59% 80
2025
Q3 		$42.4M Sell
627,756
-45,152
-7% -$3.35M 1.36% 18
2025
Q2 		$56.4M Buy
672,908
+108,427
+19% +$8.12M 2.07% 6
2025
Q1 		$40.3M Sell
564,481
-16,438
-3% -$800K 1.82% 8
2024
Q4 		$26.1M Buy
580,919
+267,585
+85% +$13.9M 1.01% 36
2024
Q3 		$15.8M Buy
313,334
+20,006
+7% +$958K 0.61% 66
2024
Q2 		$12M Sell
293,328
-7,048
-2% -$299K 0.5% 74
2024
Q1 		$12.9M Buy
300,376
+48,223
+19% +$2.18M 0.52% 82
2023
Q4 		$10.1M Buy
252,153
+3,479
+1% +$99K 0.43% 94
2023
Q3 		$7.34M Buy
+248,674
New +$1.51M 0.36% 100

Emerald Advisers's SLNO Position: Q2 2026 in Review

Emerald Advisers sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 274,138 shares — an estimated $9.18M sold.

Emerald Advisers first reported a position in SLNO in Q3 2023 and held it in 11 quarters. The position peaked at $56.4M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Emerald Advisers reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Emerald Advisers sold 274,138 Soleno Therapeutics shares in Q2 2026, an estimated $9.18M.
  • Emerald Advisers first reported a position in Soleno Therapeutics in Q3 2023 and held it in 11 quarters.
  • Emerald Advisers's Soleno Therapeutics position peaked at $56.4M in Q2 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.